Editorial: grey zone, a new area of interest in chronic hepatitis B
- Autores
- Ridruejo, Ezequiel
- Año de publicación
- 2018
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Editorial: grey zone, a new area of interest in chronic hepatitis B.hronic hepatitis B virus (HBV) infection is a major health problemworldwide. One of the main issues in the management of this diseaseis to decide which patient will benefit from antiviral treatment. In2017, the European Association for the Study of the Liver (EASL) pub-lished a new version of their Clinical Practice Guidelines (CPG) on themanagement of HBV infection and defined 5 phases in the natural his-tory of HBV: hepatitis B e-antigen (HBeAg)-positive chronic infection,HBeAg-positive chronic hepatitis, HBeAg-negative chronic infection,HBeAg-negative chronic hepatitis and HBsAg-negative phase.1Gener-ally, patients within chronic hepatitis phases need to be treated.2Most patients fall into one of these phases, but some individualsfall into an indeterminate area, and treatment decision needs to beindividualised.1,2In a recent issue of AP&T, a study by Bonacci andcolleagues describes what happen in patients falling in one of thisindeterminate areas.3They described a ?Grey Zone? (GZ) betweenHBeAg-negative chronic infection (formerly called inactive carriers[IC]) and HBeAg-negative chronic hepatitis, since HBV-DNA andALT levels may fluctuate over time making difficult a precise classifi-cation of the patient clinical situation. They defined 3 GZ categoriesbased on HBV-DNA and ALT levels and compared clinical and viro-logical outcomes with patients in the HBeAg-negative chronic infec-tion phase or IC.
Fil: Ridruejo, Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET.; Argentina - Materia
-
chronic
hepatitis B - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/88844
Ver los metadatos del registro completo
id |
CONICETDig_9b9061cdc67c90cd33bcbfea037982fd |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/88844 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Editorial: grey zone, a new area of interest in chronic hepatitis BRidruejo, Ezequielchronichepatitis Bhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Editorial: grey zone, a new area of interest in chronic hepatitis B.hronic hepatitis B virus (HBV) infection is a major health problemworldwide. One of the main issues in the management of this diseaseis to decide which patient will benefit from antiviral treatment. In2017, the European Association for the Study of the Liver (EASL) pub-lished a new version of their Clinical Practice Guidelines (CPG) on themanagement of HBV infection and defined 5 phases in the natural his-tory of HBV: hepatitis B e-antigen (HBeAg)-positive chronic infection,HBeAg-positive chronic hepatitis, HBeAg-negative chronic infection,HBeAg-negative chronic hepatitis and HBsAg-negative phase.1Gener-ally, patients within chronic hepatitis phases need to be treated.2Most patients fall into one of these phases, but some individualsfall into an indeterminate area, and treatment decision needs to beindividualised.1,2In a recent issue of AP&T, a study by Bonacci andcolleagues describes what happen in patients falling in one of thisindeterminate areas.3They described a ?Grey Zone? (GZ) betweenHBeAg-negative chronic infection (formerly called inactive carriers[IC]) and HBeAg-negative chronic hepatitis, since HBV-DNA andALT levels may fluctuate over time making difficult a precise classifi-cation of the patient clinical situation. They defined 3 GZ categoriesbased on HBV-DNA and ALT levels and compared clinical and viro-logical outcomes with patients in the HBeAg-negative chronic infec-tion phase or IC.Fil: Ridruejo, Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET.; ArgentinaWiley Blackwell Publishing, Inc2018-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/88844Ridruejo, Ezequiel; Editorial: grey zone, a new area of interest in chronic hepatitis B; Wiley Blackwell Publishing, Inc; Alimentary Pharmacology & Therapeutics.; 47; 11; 6-2018; 1547-15481746-6334CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/full/10.1111/apt.14644info:eu-repo/semantics/altIdentifier/doi/10.1111/apt.14644info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:55:16Zoai:ri.conicet.gov.ar:11336/88844instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:55:16.703CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Editorial: grey zone, a new area of interest in chronic hepatitis B |
title |
Editorial: grey zone, a new area of interest in chronic hepatitis B |
spellingShingle |
Editorial: grey zone, a new area of interest in chronic hepatitis B Ridruejo, Ezequiel chronic hepatitis B |
title_short |
Editorial: grey zone, a new area of interest in chronic hepatitis B |
title_full |
Editorial: grey zone, a new area of interest in chronic hepatitis B |
title_fullStr |
Editorial: grey zone, a new area of interest in chronic hepatitis B |
title_full_unstemmed |
Editorial: grey zone, a new area of interest in chronic hepatitis B |
title_sort |
Editorial: grey zone, a new area of interest in chronic hepatitis B |
dc.creator.none.fl_str_mv |
Ridruejo, Ezequiel |
author |
Ridruejo, Ezequiel |
author_facet |
Ridruejo, Ezequiel |
author_role |
author |
dc.subject.none.fl_str_mv |
chronic hepatitis B |
topic |
chronic hepatitis B |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Editorial: grey zone, a new area of interest in chronic hepatitis B.hronic hepatitis B virus (HBV) infection is a major health problemworldwide. One of the main issues in the management of this diseaseis to decide which patient will benefit from antiviral treatment. In2017, the European Association for the Study of the Liver (EASL) pub-lished a new version of their Clinical Practice Guidelines (CPG) on themanagement of HBV infection and defined 5 phases in the natural his-tory of HBV: hepatitis B e-antigen (HBeAg)-positive chronic infection,HBeAg-positive chronic hepatitis, HBeAg-negative chronic infection,HBeAg-negative chronic hepatitis and HBsAg-negative phase.1Gener-ally, patients within chronic hepatitis phases need to be treated.2Most patients fall into one of these phases, but some individualsfall into an indeterminate area, and treatment decision needs to beindividualised.1,2In a recent issue of AP&T, a study by Bonacci andcolleagues describes what happen in patients falling in one of thisindeterminate areas.3They described a ?Grey Zone? (GZ) betweenHBeAg-negative chronic infection (formerly called inactive carriers[IC]) and HBeAg-negative chronic hepatitis, since HBV-DNA andALT levels may fluctuate over time making difficult a precise classifi-cation of the patient clinical situation. They defined 3 GZ categoriesbased on HBV-DNA and ALT levels and compared clinical and viro-logical outcomes with patients in the HBeAg-negative chronic infec-tion phase or IC. Fil: Ridruejo, Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET.; Argentina |
description |
Editorial: grey zone, a new area of interest in chronic hepatitis B.hronic hepatitis B virus (HBV) infection is a major health problemworldwide. One of the main issues in the management of this diseaseis to decide which patient will benefit from antiviral treatment. In2017, the European Association for the Study of the Liver (EASL) pub-lished a new version of their Clinical Practice Guidelines (CPG) on themanagement of HBV infection and defined 5 phases in the natural his-tory of HBV: hepatitis B e-antigen (HBeAg)-positive chronic infection,HBeAg-positive chronic hepatitis, HBeAg-negative chronic infection,HBeAg-negative chronic hepatitis and HBsAg-negative phase.1Gener-ally, patients within chronic hepatitis phases need to be treated.2Most patients fall into one of these phases, but some individualsfall into an indeterminate area, and treatment decision needs to beindividualised.1,2In a recent issue of AP&T, a study by Bonacci andcolleagues describes what happen in patients falling in one of thisindeterminate areas.3They described a ?Grey Zone? (GZ) betweenHBeAg-negative chronic infection (formerly called inactive carriers[IC]) and HBeAg-negative chronic hepatitis, since HBV-DNA andALT levels may fluctuate over time making difficult a precise classifi-cation of the patient clinical situation. They defined 3 GZ categoriesbased on HBV-DNA and ALT levels and compared clinical and viro-logical outcomes with patients in the HBeAg-negative chronic infec-tion phase or IC. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-06 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/88844 Ridruejo, Ezequiel; Editorial: grey zone, a new area of interest in chronic hepatitis B; Wiley Blackwell Publishing, Inc; Alimentary Pharmacology & Therapeutics.; 47; 11; 6-2018; 1547-1548 1746-6334 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/88844 |
identifier_str_mv |
Ridruejo, Ezequiel; Editorial: grey zone, a new area of interest in chronic hepatitis B; Wiley Blackwell Publishing, Inc; Alimentary Pharmacology & Therapeutics.; 47; 11; 6-2018; 1547-1548 1746-6334 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/full/10.1111/apt.14644 info:eu-repo/semantics/altIdentifier/doi/10.1111/apt.14644 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Wiley Blackwell Publishing, Inc |
publisher.none.fl_str_mv |
Wiley Blackwell Publishing, Inc |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842269335108714496 |
score |
13.13397 |